What type of drug does Guanfacine belong to?

Guanfacine is a drug that acts on the central nervous system and belongs to the α2 adrenergic receptor agonist class. The main purpose of initial development was to treat high blood pressure, because it can reduce the activity of sympathetic nerves by acting on receptors in the brain, thereby reducing vascular resistance and achieving a blood pressure lowering effect. With the deepening of research, it was discovered that guanfacine also has clinical value in the neuropsychiatric field, especially in the treatment of attention deficit hyperactivity disorder (ADHD), so its scope of indications has gradually been expanded.

Compared with traditional stimulant drugsGuanfacine has a different mechanism of action. It does not improve attention by increasing the levels of dopamine or norepinephrine, but indirectly improves the function of the prefrontal cortex by regulating receptor activity, thereby improving concentration and impulse control. This makes it a more suitable choice in some patients who have poor tolerance to stimulants or suffer from sleep disorders.

From a classification perspective, guanfacine hydrochloride can be regarded as both an antihypertensive drug and a non-stimulant central nervous system drug. In the United States and Europe, sustained-release formulations of guanfacine have been approved specifically for the long-term treatment of ADHD, while immediate-release formulations are still mostly used in the cardiovascular field. This dual-use feature makes guanfacine highly flexible in clinical practice.

In China, guanfacine has not been on the market for a long time and is currently mainly used under the guidance of a doctor's prescription. Its medication safety has been verified overseas, but blood pressure and heart rate still need to be monitored in different groups of people to avoid adverse reactions such as hypotension or drowsiness. With the increasing demand for the treatment of neuropsychiatric diseases, the application prospects of guanfacine in China are also generally optimistic.

Reference materials:https://go.drugbank.com/drugs/DB01018